Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

Benzinga Newsdesk www.benzinga.com Neutral 59.8%

Neg 0% Neu 59.8% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.